Valuation: Aytu Bioscience Inc

Market Cap 21.52M 19.27M 17.78M 16.09M 30.09M 2.05B 30.57M 212M 84.62M 1.07B 80.75M 79.03M 3.4B P/E 2027 *
-2.3x
P/E 2028 * 5.91x
Enterprise Value 21.52M 19.27M 17.78M 16.09M 30.09M 2.05B 30.57M 212M 84.62M 1.07B 80.75M 79.03M 3.4B EV / Sales 2027 *
0.32x
EV / Sales 2028 * 0.25x
Free-Float
91.84%
Yield 2027 *
-
Yield 2028 * -
Manager TitleAgeSince
Chief Operating Officer 50 2015-04-15
Chief Executive Officer 51 2015-04-15
Director of Finance/CFO 44 2024-11-10
Director TitleAgeSince
Chairman 51 2015-04-15
Director/Board Member 63 2016-04-12
Chairman 59 2024-11-05
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-28.41% - - 21.52M
+6.63%+5.13%+68.86%+145.20% 1,224B
+1.53%+2.84%+47.48%+89.01% 662B
+1.68%+1.96%+29.16%+109.31% 514B
+0.52%+3.12%+54.03%+67.05% 388B
+3.83%-0.62%+69.01%+42.32% 361B
+1.01%+4.22%+34.91%+57.63% 302B
+3.99%+5.43%+7.76%+32.32% 271B
+1.97%+3.01%+57.91%+76.14% 249B
+4.03%+5.36%+39.76%+116.14% 205B
Average +1.89%+2.59%+45.43%+81.68% 464.09B
Weighted average by Cap. +1.76%+3.04%+50.72%+96.51%

Financials

2027 *2028 *
Net sales 67.91M 60.83M 56.12M 50.78M 94.96M 6.47B 96.49M 669M 267M 3.38B 255M 249M 10.72B 86.91M 77.84M 71.82M 64.99M 122M 8.28B 123M 857M 342M 4.33B 326M 319M 13.72B
Net income -11.64M -10.43M -9.62M -8.71M -16.28M -1.11B -16.55M -115M -45.8M -580M -43.7M -42.77M -1.84B 1.27M 1.14M 1.05M 950K 1.78M 121M 1.81M 12.53M 5M 63.33M 4.77M 4.67M 201M
Net Debt - -
Logo Aytu Bioscience Inc
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aytu Bioscience Inc